Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Mylan launches Potassium Chloride Extended-release Tablets

Mylan launches Potassium Chloride Extended-release Tablets

Mylan Inc. today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con. [More]

Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

Men in steady same-sex relationships where both partners are HIV negative will often forgo condoms out of a desire to preserve intimacy, even if they also have sex outside the relationship. [More]
iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. [More]
Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. [More]

EGPAF applauds new licensing agreement to improve access to HIV medication for children

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication. [More]
SIV can be entrenched in tissues before virus is detectable in blood plasma

SIV can be entrenched in tissues before virus is detectable in blood plasma

Scientists have generally believed that HIV and its monkey equivalent, SIV, gain a permanent foothold in the body very early after infection, making it difficult to completely eliminate the virus even after antiretroviral therapy has controlled it. [More]
EGPAF experts to deliver presentations at AIDS 2014

EGPAF experts to deliver presentations at AIDS 2014

Experts from the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) will give oral presentations, moderate conference events, and exhibit a variety of educational posters and abstracts related to ending AIDS in children. [More]
Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. [More]
Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
HIV self-testing increases proportion of adults initiating antiretroviral therapy

HIV self-testing increases proportion of adults initiating antiretroviral therapy

Among adults in the African country of Malawi offered HIV self-testing, optional home initiation of care compared with standard HIV care resulted in a significant increase in the proportion of adults initiating antiretroviral therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
New guidelines integrate biomedical advances and behavioral interventions for HIV people

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation. [More]

Annual HIV diagnosis rate in the U.S. decreases more than 30%: Study

The annual HIV diagnosis rate in the U.S. decreased more than 30 percent from 2002-2011, with declines observed in several key populations, although increases were found among certain age groups of men who have sex with men, especially young men, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
Discovery presents new challenges for HIV eradication efforts

Discovery presents new challenges for HIV eradication efforts

The most critical barrier for curing HIV-1 infection is the presence of the viral reservoir, the cells in which the HIV virus can lie dormant for many years and avoid elimination by antiretroviral drugs. Very little has been known about when and where the viral reservoir is established during acute HIV-1 infection, or the extent to which it is susceptible to early antiretroviral therapy (ART). [More]
Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Regular attendance at HIV primary care visits and high adherence to antiretroviral therapy (ART) are vital for people living with HIV/AIDS (PLHA), as these health behaviors lead to lowered rates of morbidity and mortality, increased quality of life, and reducing the risk of HIV transmission to others. [More]
Phase II study reveals potential biomarker for HIV vaccine

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine. [More]

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure [More]
New software-based method identifies patients with newly diagnosed HIV using EMRs

New software-based method identifies patients with newly diagnosed HIV using EMRs

A new, validated software-based method for identifying patients with newly diagnosed HIV using electronic medical records (EMRs) is described in AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers. [More]
Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan Inc. today announced that it has entered into a definitive agreement with Abbott whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business ("the Assets") in an all-stock transaction. [More]
"Expressive therapy" intervention helps HIV women, improves social support

"Expressive therapy" intervention helps HIV women, improves social support

New research from UC San Francisco shows that an "expressive therapy" group intervention conducted by The Medea Project helps women living with HIV disclose their health status and improves their social support, self-efficacy and the safety and quality of their relationships. [More]